Diabetis JSC
Single-center, prospective, minimal-risk, non-experimental usability study assessing the setup and use of the FDA-registered (Class I medical device; 510(k)-exempt) Feetsee™ home foot-monitoring system by adults with diabetes in their home environment over 8 weeks. This study in non clinical, observational pilot usability study conducted under FDA Human Factors and Usability Engineering guidance (2016).
Participants will be recruited from outpatient diabetes and podiatry clinics at UT Health San Antonio, an academic medical center. The study itself is conducted as a home-use usability study: after initial training, participants set up and use the Feetsee foot-monitoring system in their own homes, following the US IFU and in-app instructions. Data will be collected via paper/electronic CRFs, patient questionnaires, and Feetsee device/app usage logs (exported to REDCap and secure sponsor databases).
Inclusion Criteria: * Males and females aged 18 years or older * Clinical diagnosis of Type 1 or Type 2 diabetes * At least one palpable foot pulse per feet * Possess basic ability to use a smartphone or tablet * Have no prior experience with the Feetsee™ system * Be willing and able to provide informed consent Exclusion Criteria: * Active foot ulceration at enrollment * Active Charcot neuro-osteoarthropathy * Severe vascular disease (complete absence of foot pulses) * Amputation of more than three toes * Active malignancy or immunosuppressive condition * Cognitive or physical impairments p…
: after initial training, participants set up and use the Feetsee foot-monitoring system in their own homes, following the US IFU and in-app instructions. Data will be collected via paper/electronic CRFs, patient questionnaires, and Feetsee device/app usage logs (exported to REDCap and secure sponsor databases).
Arctuva estimate
Verify or correct the compensation shown for this listing.